2019:
PRECISION
ONCOLOGy
THE DATE SAVE
24-25 May 2019 ROME
HOTEL QUIRINALE, Via Nazionale 7
PROGRAMME
CONGRESS LOCATION
The conference takes place in Rome, at the Hotel Quirinale (Via Nazionale, 7 Tel: 06 4707) on 24 and 25 May 2019. The Organizing Secretariat is available to participants at the conference venue from 9.00 am on 24 May and for the whole duration of the event.
SUBSCRIPTIONS
Subscription entitles to participation in scientific work, to receiving the folder containing scientific documents, the attendance certificate and the admission to working lunch.
ATTENDANCE CERTIFICATE
The attendance certificate will be given to all participants regularly registered in the course, who will request it at the secretary desk at the end of the work.
ECM
For this course the Commissione Nazionale per la Formazione Continua in Medicina (National Commission for Refresher Courses in Medicine) (ECM) of the Ministry of Health assigns, n. 7.7 training credits for the following professional figures of PHYSICIAN AND SURGEON (oncology, pathological anatomy, pharmacology and clinical toxicology, gynaecology and obstetrics, general surgery, radiation therapy, medical technician of biomedical laboratory, urology, clinical biochemistry, medical genetics), BIOLOGIST and NURSE.
To obtain the ECM credits, it is necessary to participate in at least 90% of the scientific papers, completely fill out the ECM dossier, correctly answer to at least 75% of the questions and return the dossier to the organizational secretariat at the end of the work. Upon completing the training activity, the participant will be given an attendance certificate while the certificate showing the ECM credits will be sent after the completion of the procedure so that the questionnaires can be corrected. Speakers are entitled to 1 credit for every half hour of teaching regardless of the credits assigned to the event.
GENERAL
INFORMATIONS
FACULTY
Roberto Bordonaro P. O. Garibaldi-Nesima, Catania
Emilio Bria
Università Cattolica del Sacro Cuore, Fondazione Policlinico ‘A. Gemelli’, Roma
Ettore Capoluongo
U.O.S.D. Fondazione Policlinico
‘A. Gemelli’, IRCCS, Roma
Carlo Carnaghi Humanitas Mater Domini, Castellanza (VA)
Giacomo Cartenì A. O. Cardarelli, Napoli
Vanna Chiarion Sileni Istituto Oncologico Veneto, Padova
Saverio Cinieri A.S.L. Brindisi
Francesco Cognetti I.F.O. Regina Elena IRCCS, Roma
Pierfranco Conte Istituto Oncologico Veneto, Padova
Laura Cortesi
A.O. Policlinico Universitario, Modena
Romano Danesi Università degli Studi, Pisa
Emanuele De Luca
Azienda Ospedaliera- Universitaria an Luigi Gonzaga,
Orbassano (TO Gaetano De Rosa
Università Federico II - Napoli Angelo Del Monte
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC)
Marzia Del Re Ospedale S. Chiara, Pisa
Massimo Di Maio A.O. Ordine Mauriziano, Torino
Alessandra Fabi I. F. O. Regina Elena, Roma
Stefania Gori
Presidente Nazionale AIOM,
Direttore Oncologia Medica - IRCCS Ospedale Sacro Cuore - Don Calabria, Negrar (VR)
Francesco Grossi Ist. Naz. Ricerca Cancro, Genova
Valentina Guarneri
Istituto Oncologico Veneto IRCCS, Padova
Lorena Incorvaia
A.O.U. Policlinico “Paolo Giaccone”, Palermo
Alessandro Inno
IRCCS Ospedale Sacro Cuore - Don Calabria,
Negrar (VR) Nicla La Verde
A.S.S.T. Fatebenefratelli Sacco, Milano
Giuseppe Lombardi Istituto Oncologico Veneto, Padova
Sara Lonardi
Istituto Oncologico Veneto, Padova
Giuseppe Lo Russo
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Milano Vito Lorusso
Istituto Tumori Giovanni Paolo II, Bari
Claudio Luchini Università degli Studi, Verona
Antonio Marchetti Università G. D’Annunzio, Chieti
Paolo Marchetti
Azienda Ospedaliero-Universitaria Sant’Andrea,
Roma
Marco Merlano A. O. S. Croce e Carle, Cuneo
Enrico Mini A.O.U. Careggi, Firenze
Giorgio Minotti
Università Campus Bio-Medico, Roma
Filippo Montemurro Istituto di Candiolo IRCCS, Candiolo (To)
Federica Morano
Fondazione IRCCS Istituto Nazionale Tumori,
Milano
Emanuele Neri
Istituto Dipartimento di Ricerca Traslazionale, Università di Pisa Fabrizio Nicolis
Presidente Fondazione Aiom, IRCCS Ospedale Sacro Cuore - Don Calabria,
Negrar (VR)
Giuseppe Procopio
Fondazione IRCCS Istituto Nazionale dei Tumori,
Milano
Paola Queirolo A.O.U. S. Martino, Genova
Luigi Ruco
Università La Sapienza, Roma
Antonio Russo
A.O.U. Policlinico P. Giaccone, Palermo
Stefano Severi IRST-IRCCS, Meldola (FC) Nicola Silvestris Ospedale Giovanni Paolo II, Bari
Valentina Sini
ASL Roma1 UOSD Centro Oncologico, SS-NRM,
Roma
Pierfrancesco Tassone Università Magna Graecia, Catanzaro
Giuseppe Toffoli C.R.O.,
Aviano (PN) Stefania Tommasi
IRCCS-OSPEDALE ONCOLOGICO, Bari
Giancarlo Troncone
Università degli Studi “Federico II”, Napoli
Elena Vigliar Università Federico II, Napoli
Vittorina Zagonel
Istituto Oncologico Veneto IRCCS, Padova
PROGRAMME
24 MA Y
SESSION I A CHANGING WORLD…Moderators: F. Cognetti, L. Ruco
10.00 From histology to the molecular profile:
integrated diagnostic approach to neoplasms C. Luchini
Response Predictive factors to immunotherapeutic drugs from PDL-1 to Tumor Mutational Burden:
- 10.15 the pathologist G. Troncone, E.Vigliar - 10.25 the pharmacologist R. Danesi 10.35 The tumor microenvironment and new drugs
F. Cognetti 10.50 Discussion
SESSION II UNANSWERED QUERIES
Moderators: M. Merlano, E. Mini
11.00 “Driver” mutation and “Passenger” mutation:
what is the clinical meaning?
S. Tommasi
11.15 The new immune-related response criteria (iRECIST):
are always adequate G. Lo Russo
11.30 The design and conduct of clinical trials in the era of precision oncology:
what is changing?
E. De Luca, M. Di Maio 12.00 Discussion
SESSION III BRCA MUTATED OVARIAN CARCINOMA
Moderators: G. De Rosa, N. La Verde
12.00 AIOM-SIGU-SIBIOP-SIAPEC-IAP 2019 recommendations L. Cortesi
12.15 The use of new genomic technologies in BRCA mutated ovarian cancer patients: what information?
E. Capoluongo
12.30 Germinal pharmacogenetics G. Toffoli
12.45 Discussion 13.30 Working Lunch
SESSION IV ONCOGENE-ADDICTED NSCLC
Moderators: F. Grossi, A. Inno
14.30 The development of resistances:
clinical impact and therapeutic strategies M. Del Re
14.45 Liquid biopsy recommendations AIOM -SIAPEC-IAP-SIF-SIBioC A. Russo
15.00 Criteria of response during therapies in TKI:
clinical or molecular criteria?
E. Bria
15.15 The new targets: ROS1, MEK, NTRK A. Del Monte
15.30 Discussion
SESSION V COLORECTAL CARCINOMA
Moderators: C. Carnaghi, V. Zagonel
16.00 Definition, effect, clinical course, therapies S. Lonardi
16.15 New therapies and scientific evidence F. Morano
16.30 Position of regulatory bodies: FDA, EMA, AIFA R. Bordonaro
16.45 Discussion
PROGRAMME
24 MA Y
SESSION VI MALIGNANT MELANOMA, CEREBRAL AND UROLOGICAL NEOPLASMS
Moderators: G.Cartenì, P. Queirolo
17.15 2019: adjuvant treatment of malignant melanoma V.Chiarion Sileni
17.30 New targets in brain neoplasms G. Lombardi
17.45 BRCA2 and prostate carcinoma G. Procopio
18.00 Urological malignancies and immunotherapy: which targets?
L. Incorvaia
18.15 Discussion
18.30 Conclusion of works
PROGRAMME
24 MA Y
PROGRAMME
24 MA Y
SESSION VII BREAST CANCER
Moderators: S. Cinieri, S. Gori
8.30 PI3KA mutations and ER mutations:
what impact on the outcome of breast cancer patients?
- the pharmacologist G.Minotti - the oncologist A. Fabi
9.15 BRCA mutated metastatic breast cancer:
What is the role of PARP-I?
V.Guarneri
9.30 Immunotherapy in breast cancer: what evidence?
V. Sini 9.45 Discussion
Sessione VIII NEW FRONTIERS
Moderators: V. Lorusso, S.Severi 10.00 Radio receptor therapy
S.Severi 10.20 Radiomics
E. Neri 10.40 Discussion 11.00 Coffee Break
25 MA Y
PROGRAMME
SESSION IX THE AGNOSTIC-TISSUE PRECISION MEDICINE: AN EMERGING APPROACH
Moderators: N.Silvestris, P. Tassone
11.30 Rational and therapeutic bases P. Marchetti
11.45 New targets: are they always clinically useful?
F. Montemurro
12.00 Ongoing clinical studies P. Marchetti
12.15 Patients’ requests F. Nicolis
12.30 Reading: The importance of interdisciplinary working groups in the age of precision oncology. The Molecular Tumor Board (MTB):
from clinical indications to regulatory contexts P. Conte
12.50 Discussion
13.15 Conclusions
PROGRAMME PARALLEL SESSION
25 MA Y
PARALLEL SESSION AIOM FOUNDATION MEETS PATIENTS AND CITIZENSModerator: F. Nicolis
09.00 Precision oncology: characterize the tumor to decide on the appropriate treatment
A. Marchetti
09.15 Molecular target therapies in oncology: what results?
A. Russo
09.30 Immunotherapy in oncology: results and perspectives A. Fabi
09.45 Discussion
Patients ask … oncologists answer
11.30 Conclusions
Sede di Roma
Via Domenico Cimarosa 18 - 00198 Roma Tel. 068553259 - Fax 068553221
[email protected] Sede di Milano
Via Enrico Nöe 23 - 20133 Milano Tel. 0226683129 - Fax 0259610555
SEGRETERIA ORGANIZZATIVA AIOM Servizi Srl
Servizi Provider ECM
ISO 9001
AIOM
Via Enrico Nöe 23 - 20133 Milano Tel. 0270630279 - Fax 022360018
[email protected] www.aiom.it
FONDAZIONE AIOM Via Enrico Nöe 23 - 20133 Milano Tel. 0226683335 - Fax 0259610555
[email protected] www.fondazioneaiom.it
GRAZIE ALLA SPONSORIZZAZIONE NON CONDIZIONANTE DI:
